Amgen Inc.

Cytokinetics, Inc.

Stephanie Azali

Ron C Kelly

Mary Chaves

Darren Leonard Reid

Patricia Lopez

Albert Kudzovi Amegadzie

Roman Shimanovich

Prashant Agarwal

Steven Mennen

Osama Suleiman

Ashraf Wilsily

Mark Wright

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Solid state forms

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2 (1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Polymorphs and cocrystals of a cardiac troponin activator

Growing community of inventors

Woodland Hills, CA, United States of America

Stephanie Azali